Abstract
Dupuytren’s contracture is a superficial fibrotic disease of the hands that causes flexion contractures of the affected fingers. Diabetes mellitus (DM) is a risk factor for Dupuytren’s contracture. However, the exact underlying mechanisms by which DM is involved in its development and progression remain unknown. This study investigated the involvement of glycometabolic disorders in the pathogenesis of Dupuytren’s contracture. RNA sequencing revealed that S100A4 expression was significantly increased in Dupuytren’s contracture-derived fibroblasts under high-glucose conditions compared with low-glucose conditions, and this finding was confirmed by immunoblotting and enzyme-linked immunosorbent assay. S100A4 expression in Dupuytren’s contracture tissues was significantly higher in patients with diabetes than in those without. S100A4 was expressed in several cell types, including fibroblasts, myofibroblasts, and macrophages. However, the expression of its receptor, Toll-like receptor 4 (TLR4), was predominantly detected in CD68-expressing macrophages. Furthermore, recombinant S100A4 treatment significantly increased transforming growth factor-beta 1 (TGF-β1) expression, which is a central mediator of fibrosis, in macrophages. Pharmacological inhibition of TLR4 suppresses TGF-β1 upregulation via S100A4. Thus, the S100A4–TLR4–TGF-β axis could be a potential therapeutic target for Dupuytren’s contracture in diabetic patients.
Acknowledgements
We thank Miki Hirosawa for technical support and Editage (www.editage.jp) for English language editing.
Funding
S.K. discloses support for the research of this work from the Takeda Science Foundation and the Nakatomi Foundation. S.K., A.H., and H.A. disclose support for the research of this work from JSPS KAKENHI [24K12303]. K.K. discloses support for the research of this work from the Japan Orthopaedics and Traumatology Research Foundation [Grant No. 637]. Y.Y., N.S., A.G., R.M., H.H., and Y.I. declare no relevant funding.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Supplementary information
Source data
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Kato, K., Komura, S., Yanagihara, Y. et al. S100A4–TLR4–TGF-β axis as a therapeutic target for Dupuytren’s contracture in diabetic patients. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03167-y
Received:
Revised:
Accepted:
Published:
DOI: https://doi.org/10.1038/s41420-026-03167-y
